{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["22(1)"],"submitter":["Mostaza JM"],"funding":["Ferrer Internacional SA"],"pubmed_abstract":["<h4>Background</h4>Cardiovascular (CV) polypills are a useful baseline treatment to prevent CV diseases by combining different drug classes in a single pill to simultaneously target more than one risk factor. The aim of the present trial was to determine whether the treatment with the CNIC-polypill was at least non-inferior to usual care in terms of low-density lipoprotein cholesterol (LDL-c) and systolic BP (SBP) values in subjects at high or very high risk without a previous CV event.<h4>Methods</h4>The VULCANO was an international, multicentre open-label trial involving 492 participants recruited from hospital clinics or primary care centres. Patients were randomised to the CNIC-polypill -containing aspirin, atorvastatin, and ramipril- or usual care. The primary outcome was the comparis"],"journal":["BMC cardiovascular disorders"],"pagination":["560"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9773517"],"repository":["biostudies-literature"],"pubmed_title":["Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event: the international VULCANO randomised clinical trial."],"pmcid":["PMC9773517"],"pubmed_authors":["Carrasco Franco FJ","Calderon Sandubete E","VULCANO investigators","Castiella Herrero J","Alvarez Sala L","Guijarro C","Cuixart Costa L","Suarez Tembra M","Garcia Vallejo O","Pedro-Botet Montoya JC","Jansen Chaparro S","Araujo F","Cunha V","Sobrino J","Santos C","Borrayo G","Alvarez Sanchez C","Murcia Zaragoza JM","Abellan Aleman J","Espinosa J","Moura J","Coloma Bazan E","Pose A","Bonilla Rovira F","Cabezon Mariscal J","De la Pena Fernandez A","Marques Da Silva P","Orozco Beltran D","Suarez Fernandez C","Civeira F","Masana Marin L","Castellano Vazquez JM","Mostaza JM","Rovira Daudi E","Perez P","Brotons C","Escobar Jimenez L","Cosin-Sales J","Arroyo Diaz JA","Bianchi Llave JL","Cuenca Acevedo R","Gomez-Huelgas R","Martinez-Hervas Alonso MA","Tamarit JJ","Alfonso Megido J","Araujo FP","Cubo Romano MP","Rico Corral MA","Diaz Diaz JL","Ruiz E","Valdivieso Felices P","Diaz Rodriguez A","Suarez-Fernandez C","Rosas Peralta M","Mostaza Prieto JM"],"additional_accession":[]},"is_claimable":false,"name":"Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event: the international VULCANO randomised clinical trial.","description":"<h4>Background</h4>Cardiovascular (CV) polypills are a useful baseline treatment to prevent CV diseases by combining different drug classes in a single pill to simultaneously target more than one risk factor. The aim of the present trial was to determine whether the treatment with the CNIC-polypill was at least non-inferior to usual care in terms of low-density lipoprotein cholesterol (LDL-c) and systolic BP (SBP) values in subjects at high or very high risk without a previous CV event.<h4>Methods</h4>The VULCANO was an international, multicentre open-label trial involving 492 participants recruited from hospital clinics or primary care centres. Patients were randomised to the CNIC-polypill -containing aspirin, atorvastatin, and ramipril- or usual care. The primary outcome was the comparis","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2026-05-28T21:28:28.182Z","creation":"2025-04-19T22:46:22.363Z"},"accession":"S-EPMC9773517","cross_references":{"pubmed":["36550424"],"doi":["10.1186/s12872-022-03013-w"]}}